TY - JOUR
T1 - Association between vascular access dysfunction and subsequent major adverse cardiovascular events in patients on hemodialysis
T2 - A population-based nested case-control study
AU - Kuo, Te Hui
AU - Tseng, Chien Tzu
AU - Lin, Wei Hung
AU - Chao, Jo Yen
AU - Wang, Wei Ming
AU - Li, Chung Yi
AU - Wang, Ming Cheng
N1 - Publisher Copyright:
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - The association between dialysis vascular access dysfunction and the risk of developing major adverse cardiovascular events (MACE) in hemodialysis patients is unclear and has not yet been investigated. We analyzed data from the National Health Insurance Research Database of Taiwan to quantify this association. Adopting a case-control design nested within a cohort of patients who received hemodialysis from 2001 to 2010, we identified 9711 incident cases of MACE during the stage of stable maintenance dialysis and 19,422 randomly selected controls matched to cases on age, gender, and duration of dialysis. Events of vascular access dysfunction in the 6-month period before the date of MACE onset (ie, index date) for cases and before index dates for controls were evaluated retrospectively. The presence of vascular access dysfunction was associated with a 1.385-fold higher odds of developing MACE as estimated from the logistic regression analysis. This represents a significantly increased adjusted odds ratio (OR) at 1.268 (95% confidence interval [CI]=1.186-1.355) after adjustment for comorbidities and calendar years of initiating dialysis. We also noted a significant exposure-response trend (P<0.001) between the frequency of vascular access dysfunction and MACE, with the greatest risk (adjusted OR=1.840, 95% CI=1.549-2.186) noted in patients with ≥3 vascular access events. We concluded that dialysis vascular access dysfunction was significantly associated with an increased risk of MACE. Hence, vascular access failure can be an early sign for MACE in patients receiving maintenance hemodialysis. Active monitoring and treatment of cardiovascular risk factors and related diseases, not merely managing vascular access dysfunction, would be required to reduce the risk of MACE.
AB - The association between dialysis vascular access dysfunction and the risk of developing major adverse cardiovascular events (MACE) in hemodialysis patients is unclear and has not yet been investigated. We analyzed data from the National Health Insurance Research Database of Taiwan to quantify this association. Adopting a case-control design nested within a cohort of patients who received hemodialysis from 2001 to 2010, we identified 9711 incident cases of MACE during the stage of stable maintenance dialysis and 19,422 randomly selected controls matched to cases on age, gender, and duration of dialysis. Events of vascular access dysfunction in the 6-month period before the date of MACE onset (ie, index date) for cases and before index dates for controls were evaluated retrospectively. The presence of vascular access dysfunction was associated with a 1.385-fold higher odds of developing MACE as estimated from the logistic regression analysis. This represents a significantly increased adjusted odds ratio (OR) at 1.268 (95% confidence interval [CI]=1.186-1.355) after adjustment for comorbidities and calendar years of initiating dialysis. We also noted a significant exposure-response trend (P<0.001) between the frequency of vascular access dysfunction and MACE, with the greatest risk (adjusted OR=1.840, 95% CI=1.549-2.186) noted in patients with ≥3 vascular access events. We concluded that dialysis vascular access dysfunction was significantly associated with an increased risk of MACE. Hence, vascular access failure can be an early sign for MACE in patients receiving maintenance hemodialysis. Active monitoring and treatment of cardiovascular risk factors and related diseases, not merely managing vascular access dysfunction, would be required to reduce the risk of MACE.
UR - http://www.scopus.com/inward/record.url?scp=84942519990&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942519990&partnerID=8YFLogxK
U2 - 10.1097/MD.0000000000001032
DO - 10.1097/MD.0000000000001032
M3 - Article
C2 - 26131808
AN - SCOPUS:84942519990
VL - 94
JO - Medicine (United States)
JF - Medicine (United States)
SN - 0025-7974
IS - 26
M1 - e1032
ER -